Live feed12:57:00·3mPRReleasevia QuantisnowPfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast CancerByQuantisnow·Wall Street's wire, on your screen.PFE· Pfizer Inc.Health Care
